Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $930.00

Key Points

• Jefferies raised Regeneron’s price target to $930 from $870 and maintained a “buy” rating, implying 25.63% upside from the cited closing price. Analysts overall rate the stock “Moderate Buy,” with a consensus target of $809.50.
• Regeneron reported strong quarterly results, posting $14.29 in EPS versus $10.16 expected and $4.29 billion in revenue, up 16.7% year over year.
• The company’s outlook is supported by an expanded Sanofi alliance worth up to $1 billion upfront and $7 billion in potential milestones, along with promising early data for its obesity and cancer pipeline programs; however, these programs remain subject to further clinical and regulatory validation.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price target upped by investment analysts at Jefferies Financial Group from $870.00 to $930.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Jefferies Financial Group's target price points to a potential upside of 25.63% from the company's previous close.

REGN has been the subject of a number of other research reports. Wells Fargo & Company upped their price objective on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. Piper Sandler lowered their price target on Regeneron Pharmaceuticals from $855.00 to $854.00 and set an "overweight" rating on the stock in a report on Thursday, July 9th. Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Sunday, September 20th. Guggenheim lifted their price target on shares of Regeneron Pharmaceuticals from $1,000.00 to $1,030.00 and gave the company a "buy" rating in a report on Monday, August 3rd. Finally, Truist Financial increased their price objective on shares of Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the company a "buy" rating in a report on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and nine have assigned a Hold rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus target price of $809.50.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded down $17.98 during trading hours on Thursday, reaching $740.29. 623,687 shares of the company traded hands, compared to its average volume of 829,401. The firm has a 50-day moving average price of $785.06 and a 200 day moving average price of $720.91. The company has a market cap of $76.22 billion, a P/E ratio of 18.34, a P/E/G ratio of 1.47 and a beta of 0.20. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.34 and a quick ratio of 2.78. Regeneron Pharmaceuticals has a 12-month low of $541.00 and a 12-month high of $859.34.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping analysts' consensus estimates of $10.16 by $4.13. The company had revenue of $4.29 billion for the quarter, compared to analysts' expectations of $3.82 billion. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The firm's revenue was up 16.7% compared to the same quarter last year. During the same quarter last year, the business earned $12.81 EPS. As a group, sell-side analysts predict that Regeneron Pharmaceuticals will post 44.25 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Marion Mccourt sold 1,131 shares of the business's stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $857.39, for a total transaction of $969,708.09. Following the transaction, the executive vice president owned 12,003 shares of the company's stock, valued at approximately $10,291,252.17. The trade was a 8.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Huda Zoghbi sold 800 shares of the stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $640,000.00. Following the sale, the director owned 1,703 shares in the company, valued at $1,362,400. The trade was a 31.96% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 3,946 shares of company stock valued at $3,302,458 in the last ninety days. Insiders own 6.97% of the company's stock.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently made changes to their positions in the company. BlackRock Inc. bought a new stake in Regeneron Pharmaceuticals in the second quarter worth about $5,682,636,000. State Street Corp raised its holdings in shares of Regeneron Pharmaceuticals by 3.6% in the second quarter. State Street Corp now owns 4,834,688 shares of the biopharmaceutical company's stock worth $3,014,621,000 after buying an additional 170,210 shares during the period. Franklin Resources Inc. lifted its stake in shares of Regeneron Pharmaceuticals by 4.4% during the 4th quarter. Franklin Resources Inc. now owns 2,560,004 shares of the biopharmaceutical company's stock worth $1,975,990,000 after acquiring an additional 106,861 shares during the last quarter. Nuveen LLC boosted its holdings in Regeneron Pharmaceuticals by 71.1% during the 4th quarter. Nuveen LLC now owns 2,010,517 shares of the biopharmaceutical company's stock valued at $1,551,858,000 after acquiring an additional 835,240 shares during the period. Finally, Invesco Ltd. boosted its holdings in Regeneron Pharmaceuticals by 7.2% during the 4th quarter. Invesco Ltd. now owns 1,591,105 shares of the biopharmaceutical company's stock valued at $1,228,127,000 after acquiring an additional 106,632 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Expanded Sanofi alliance provides substantial upfront funding. Regeneron will receive $1 billion upfront and could earn up to $7 billion in milestones by adding several next-generation, long-acting immunology antibodies—including REGN20423—to its collaboration with Sanofi. The companies will share development and commercialization costs and future profits, strengthening Regeneron’s pipeline and liquidity. Regeneron and Sanofi Expand Global Alliance
• Positive Sentiment: Promising obesity-treatment data support a potential differentiated role for trevogrumab. In the Phase 2 COURAGE trial, trevogrumab preserved approximately 70% of muscle loss associated with semaglutide in a predefined MRI substudy. Patients with low baseline lean mass appeared to receive particular benefit, potentially addressing a key concern with GLP-1 weight-loss drugs. Phase 2 COURAGE Trial
• Positive Sentiment: Ubamatamab showed encouraging early cancer efficacy. The MUC16xCD3 therapy produced a 73% objective response rate and 11-month median progression-free survival in 11 heavily pretreated patients with recurrent low-grade serous ovarian cancer. The results could support further development in a cancer type with limited treatment options, although the sample was very small. Ubamatamab LGSOC Results
• Positive Sentiment: Analyst support improved. Argus upgraded REGN from “hold” to “buy” and assigned an $850 price target, implying meaningful upside based on the cited reference price. Argus Upgrade
• Neutral Sentiment: Analyst opinion remains mixed. RBC maintained a “Sector Perform” rating, suggesting the new announcements may already be partly reflected in the valuation and that investors may want additional clinical or commercial validation.
• Negative Sentiment: Pipeline results remain early-stage. Trevogrumab and ubamatamab still require additional clinical testing, while the Sanofi deal’s potential milestones are contingent on development and regulatory success. These factors may limit the immediate earnings impact and help explain why REGN has decreased despite positive news.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc is a biotechnology company that discovers, develops and commercializes medicines for serious medical conditions. The company uses human genetics, antibody technology and other biological research platforms to develop treatments in areas including eye diseases, cancer, cardiovascular and metabolic disorders, inflammatory diseases, infectious diseases and rare conditions.

Regeneron's marketed products include EYLEA and EYLEA HD for certain retinal diseases; Dupixent, developed and commercialized with Sanofi, for multiple allergic and inflammatory conditions; Libtayo for certain cancers; Praluent for high cholesterol; Kevzara for rheumatoid arthritis and other inflammatory diseases; Evkeeza for homozygous familial hypercholesterolemia; and Veopoz for a rare immune-mediated disorder.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.